Kunena :: Тема: Posted by Alfred on 29.11.2016 6:10:27: lung cancer drug tarceva side effects (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Alfred on 29.11.2016 6:10:27: lung cancer drug tarceva side effects

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Alfred on 29.11.2016 6:10:27: lung cancer drug tarceva side effects

Страница:
1
2

ТЕМА: Posted by Alfred on 29.11.2016 6:10:27: lung cancer drug tarceva side effects

Posted by Alfred on 29.11.2016 6:10:27: lung cancer drug tarceva side effects 7 года 5 мес. назад #903

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
We established that the key erlotinib-resistance mutation is T790M, whereas mutations of C797S and G796R strongly impaired inhibition by CI-1033. We predicted that combination of erlotinib and CI-1033 should significantly reduce the number of resistant clones, since proliferation of cells expressing EGFR-T790M was potently inhibited by CI-1033, whereas erlotinib efficiently inhibited C797S. The resistance screen was therefore repeated in the presence of various concentrations of erlotinib and CI-1033. We observed that increasing concentrations of either erlotinib or CI-1033 inversely correlated with the number of resistant colonies obtained (Figure 5 ). As predicted, the combination of erlotinib with CI-1033 was extremely effective in preventing the formation of resistant colonies, presumably because each inhibitor exerts selective pressure in a complementary manner (Figure 5 ).
din-almaty.gov.kz/index.php?option=com_k...1&Itemid=719&lang=ru
Erlotinib hydrochloride 183319-69-9
kras-rogaining.ru/index.php?option=com_k...=3&id=22120&Itemid=0
If you experience drowsiness, dizziness, hypotension or a headache as side-effects when eating Erlonat Tablet medicine then it may not be safe to drive a vehicle or operate heavy machinery. One should not drive a vehicle if eating the medicine makes you drowsy, dizzy or lowers your blood-pressure extensively. Pharmacists also advise patients not to drink alcohol with medicines as alcohol intensifies drowsiness side-effects. Please check for these effects on your body when using Erlonat Tablet. Always consult with your doctor for recommendations specific to your body and health conditions.
MAB C225(CETUXIMAB)(ANTI-EGFR) OSI-774, TARCEVA (ERLOTINIB) Lung Adenocarcinoma Lung cancer
Co-treatment with MPT0E028 and erlotinib suppresses the growth of erlotinib-resistant tumor xenografts in vivo
biozona.com.ua/forum/post.html
Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR 21. J Clin Oncol . 2008;26(26):4268–4275.
Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol . 2009;4(11):1415–1419.
Randomization is like flipping a coin. The treatment will be assigned by chance. This procedure is commonly used in clinical trials when new treatment approaches are being tested, and when there is uncertainty about the best treatment approach. Participants with early-stage lung cancers with the EGFR gene mutation will be referred to the treatment trial evaluating erlotinib and will be randomly assigned to receive erlotinib or a placebo because the benefit of erlotinib is uncertain in this group. Likewise, participants with early-stage lung cancers with an ALK gene rearrangement will be referred to the treatment trial evaluating crizotinib and will be randomly assigned to receive crizotinib or placebo because the benefit of crizotinib is uncertain in this group. In all cases, a participant will already have received any standard therapy (usually chemotherapy with or without radiation) prescribed by their treating physician.
chitogrito.ru/index.php/forum/3-nebolsha...3909-tarceva-2-linea
Chordomas are rare primary bone tumors that occur along the neuraxis. Primary treatment is surgery, often followed by radiotherapy. Treatment options for patients with recurrence are limited and, notably, there are no FDA approved therapeutic agents. Development of therapeutic options has been limited by the paucity of preclinical model systems. We have established and previously reported the initial characterization of the first patient-derived chordoma xenograft model. In this study, we further characterize this model and demonstrate that it continues to resemble the original patient tumor histologically and immunohistochemically, maintains nuclear expression of brachyury, and is highly concordant with the original patient tumor by whole genome genotyping. Pathway analysis of this xenograft demonstrates activation of epidermal growth factor receptor (EGFR). In vitro studies demonstrate that two small molecule inhibitors of EGFR, erlotinib and gefitinib, inhibit proliferation of the chordoma cell line U-CH 1. We further demonstrate that erlotinib significantly inhibits chordoma growth in vivo . Evaluation of tumors post-treatment reveals that erlotinib reduces phosphorylation of EGFR. This is the first demonstration of antitumor activity in a patient-derived chordoma xenograft model and these findings support further evaluation of EGFR inhibitors in this disease.
Of the 19 patients with mutation status detected, responses to erlotinib showed one PR, four SD and one PD in the EGFR mutation subgroup and two PR, four SD and seven PD in the wild-type EGFR subgroup. Therefore EGFR mutation predicted better a DCR for erlotinib treatment (5 of 6 [83.3%] in EGFR mutants vs. 6 of 13 [46.2%] in wild-type EGFR, P = 0.177) (Table 3 ).
Drug: erlotinib Drug: gefitinib
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer
Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC.
Drug: ASP8273 Drug: Erlotinib Drug: Gefitinib
irenmarket.com/index.php?option=com_fire...tid=2&id=36601#36601
The drug, whose chemical name is erlotinib, was jointly invented by Pfizer Inc. and OSI Pharmaceuticals Inc. It was licensed to F Hoffmann-La Roche Ltd, which launched Tarceva in India in 2006, after securing a product patent here.
A phase II study from Canada evaluated the role of erlotinib in combination with cisplatin in patients with recurrent or metastatic HNSCC. Disease stabilization was achieved in 49% of patients, and the intention-to-treat response rate was 21%. The median progression-free survival was 3.3 months, and the median overall survival was 7.9 months. The incidence of grade 3 or higher toxicity was minimal. Patients who developed higher-grade rashes during the first cycle had better survival outcomes. This study concluded that this regimen (cisplatin + erlotinib) was well tolerated and convenient in its delivery, with an antitumor activity comparable to standard combination chemotherapy regimens in patients with recurrent or metastatic HNSCC. [49 ]
In 2011 Brian Shields, a former Tarceva sales representative and product manager, filed the whistleblower lawsuit claiming violations of the False Claims Act. This federal law allows individuals to file lawsuits as a stand-in for the federal government in claims that a defendant defrauded the federal government. In cases such as these the allegations would be that the defendant sold the government (through Medicare, Medicaid, VA hospitals) a pharmaceutical under false pretenses, claiming it would work while knowing it would not.
I agree with Dr Walko that it would be really useful to hear from anyone who has had experience with these generic alternatives – we’ve had similar questions from India about cheaper alternative versions of Tarceva. Waterspring, Is it worth contacting AstraZeneca, explaining your father’s situation and asking if they can help in any way with the cost of the Iressa? They may say no, but it is worth a try. Best of luck.
podolpalace.kiev.ua/index.php?option=com...catid=9&id=6265#6265
Combination of erlotinib and trametinib leads to improved efficacy in vivo. A. Mice bearing PC9-v tumors were treated with the indicated drugs for 4 weeks. Tumor growth was measured every week (ten mice per group). * P <0.05, ANOVA followed by Tukey's post-test. B. Mice bearing ER1 or ER2 tumors were treated with the indicated drugs for 4 weeks. Tumor growth was measured every week (ten mice per group). * P <0.05, ANOVA followed by Tukey's post-test. C. Immunohistochemical staining of Ki-67 and cleaved caspase-3 in tumor xenograft sections.
www.pneumatica.com.ua/component/kunena/2...urvival?lang=ru#6003
In summary, this study performed constructive investigations of changes in the activity of the c-MET-PI3K-AKT pathway under the combined treatment with erlotinib and radiation and the regulatory effects of blocking the c-MET-PI3K-AKT pathway on the radiosensitizing effect of erlotinib. Our findings revealed an important mechanism for cell survival under the combined treatment with erlotinib and radiation and provided a new experimental basis for further enhancing the radiosensitizing effect of erlotinib. Although only in vitro experiments were performed in this study and many questions remained to be fully explored, we believe that with further in-depth basic research, erlotinib-induced radiosensitization will achieve superior efficacy and possess a broad clinical application.
The BR.21 study established erlotinib as the standard of care for NSCLC patients who have experienced treatment failure with standard chemotherapy for advanced disease based on a significant survival benefit and improved QOL. 25 ,29 In this retrospective analysis of BR.21, we demonstrate that there is no significant difference in benefit (survival, response, and QOL) between elderly and young patients. Although the HR for survival was numerically lower in the elderly, the test of interaction was not significant. Lack of interaction by age is further supported by the similar and statistically significant progression-free survival improvement seen in both young and elderly patients.
TTP to Erlotinib (days)
How is erlotinib given (administered)? Erlotinib is given in the form of a pill and is taken orally, typically once per day.
Erlotinib hydrochloride CAS: 183319-69-9 free sample sent